Published in Cancer Gene Therapy Week, October 13th, 2003
"In this study, a panel of 39 primary malignant fibrous histiocytomas (MFH) of high malignancy grade were characterized for chromosomal alterations. The results were then evaluated in relation to the survival and the occurrence of recurrent disease during follow-up for an average period of 63 months," researchers in Sweden report.
"Chromosomal alterations detected by comparative genomic hybridization (CGH) were recorded in 37 of the 39 cases analyzed. The most frequent CGH abnormalities were gains of 17p, 20q, 16p, 17q, 1p31, 7q21, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Gene Therapy Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.